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Background: Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority
of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved.
Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction and maintenance treatment in an
intensified treatment concept, including high dose melphalan (200 mg/m2), has resulted in increased CR rates, and
is considered the standard of care for younger patients. Elotuzumab in combination with lenalidomide and
dexamethasone has given better results as lenalidomide and dexamethasone alone in a phase III trial. The GMMG-
HD6 trial will be the first phase III trial investigating the role of elotuzumab in combination with bortezomib,
lenalidomide and dexamethasone (VRD) induction/consolidation and lenalidomide maintenance within a high dose
concept.
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Methods: GMMG-HD6 is a randomized, open, multicenter phase III trial. The planned recruitment number is 564
NDMM patients. All patients will receive 4 VRD cycles as induction and undergo peripheral blood stem cell
mobilization and harvesting. Thereafter they will be treated with high dose melphalan therapy plus autologous
stem cell transplantation followed by 2 cycles of VRD consolidation and lenalidomide maintenance. Patients in arm
B1 + B2 will additionally receive elotuzumab in the induction phase, whereas patients in A2 + B2 will be treated
with elotuzumab added to consolidation and maintenance. The primary endpoint of the trial is PFS. Secondary
objectives and endpoints are OS, CR rates after induction therapy comparing the two arms VRD (A1 + A2) vs VRD +
elotuzumab (B1 + B2), CR rates after consolidation treatment, best response to treatment during the study, time to
progression (TTP), duration of response (DOR), toxicity and quality of life.
Results: Since this is the publication of a study protocol of an ongoing study, no results can be presented.
Discussion: This phase III trial is designed to evaluate whether the addition of elotuzumab to an intensified
treatment concept with high dose melphalan chemotherapy plus autologous stem cell transplantation and
induction, consolidation and maintenance treatment with bortezomib and lenalidomide is able to improve PFS
compared to the same concept without elotuzumab.
Trial registration: NCT02495922 on June 24th, 2015.
Keywords: Multiple myeloma, elotuzumab, autologous stem cell transplant, high-dose chemotherapyBackground
Multiple myeloma (MM) is a malignancy of plasma cells
and is the second most common hematological malig-
nancy. The incidence rate in Europe is 4-7/100,000 per
year. Approximately 5,700 cases are diagnosed in
Germany each year [1]. As the disease progresses, mor-
bidity and eventually mortality are caused by impaired
immune system, skeletal destruction, anemia and renal
failure. Despite major advances in therapy, multiple
myeloma is still an incurable malignancy in the majority
of patients.
Currently an intensified treatment concept including
induction therapy, high dose melphalan (200 mg/m2)
and subsequent consolidation/maintenance therapy is
considered the standard treatment for MM patients up
to the age of 70 years [1–4]. Incorporation of new drugs
in induction treatment for tumor reduction and in main-
tenance therapy has resulted in increased CR rates. Me-
dian progression-free survival (PFS) after HDT in
current standard approaches reaches 3 to 4, overall sur-
vival 9 to 11 years. Ten to 20% of intensively treated pa-
tients will be in remission more than 10 years [5]. Some
of these long-term CR patients will likely be cured. To
increase survival, deeper remissions (i.e. CR) translating
into longer PFS need to be achieved, and patient out-
come needs to be interpreted on the background of
current substratification by molecular (gene expression
profiling [GEP] and/or interphase fluorescence in situ
hybridization [iFISH]) and imaging means.
The combination of bortezomib, lenalidomide and dexa-
methasone (VRD regimen) is a well-established three drug
combination incorporating two “new drugs” for induction
therapy in previously untreated multiple myeloma.VRD has shown to be highly active and well tolerated
[6–11] and is widely used in the US as standard therapy
prior to and following HDT. VRD will be given in the
GMMG-HD6 trial as background treatment for all study
patients for induction therapy prior to a standard intensi-
fied therapy and for subsequent consolidation treatment.
Maintenance therapy after HDT prolongs duration of
the response [12, 13]. The benefit of lenalidomide main-
tenance after HDT in terms of prolongation of PFS has
been shown in several randomized trials [14, 15], with
one of those also observing a superior OS [15]. Within
the GMMG-HD6 trial, all patients are intended to re-
ceive lenalidomide maintenance.
Elotuzumab (BMS-901608; formerly known as
HuLuc63) is a humanized recombinant monoclonal
IgG1 antibody product directed to human SLAMF7
antigen (also known as CS1, CD2- subset-1), a cell
surface glycoprotein that is highly expressed on MM
cells. The proposed mechanism of action of elotuzu-
mab involves natural killer (NK) antibody dependent
cell-mediated cytotoxicity (ADCC), since elotuzumab
kills MM cell lines in vitro in the presence of periph-
eral blood mononuclear cells (PBMCs) or purified NK
cells. Because of its potent antitumor activity, elotuzu-
mab is being developed for the treatment of MM. Data
from a phase III trial (ELOQUENT-2) comparing
elotuzumab in combination with lenalidomide and
dexamethasone versus lenalidomide/dexamethasone
alone, demonstrated an PFS advantage of 19.4 vs 14.9
months in relapsed/refractory MM patients [16, 17].
The combination of VRD plus elotuzumab is investi-
gated by the Southwest Oncology Group in the US in a
phase I/II trial for newly diagnosed high risk myeloma
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VRD plus elotuzumab combination in patients eligible for
HDTand ASCT showed a low incidence of high grade toxic-
ities, although there were two deaths in the study group [19].
Main research question of the GMMG-HD6 trial is to evalu-
ate the effect of elotuzumab in induction /consolidation and
maintenance therapy in previously untreated myeloma pa-
tients in a randomized setting. Given the previously de-
scribed study results, an improvement of the therapeutic
results by the addition of this humanized monoclonal anti-
body can be expected. Elotuzumab was the first antibody in
myeloma with an FDA and EMA approval. To date, two
phase III studies evaluate elotuzumab in first line and in
1st-3rd relapse in the non-transplant setting. Results of phase
I, II and phase III trials evaluating the combination of elotu-
zumab and bortezomib or lenalidomide and dexamethasone
show very good tolerability and high response rates in pa-
tients with relapsed/refractory myeloma [20, 21]. While the
results of use of elotuzumab in monotherapy were modest
with stable disease as best response [22] the combination
with lenalidomide and dexamethasone has given excellent
results with >80% partial response in relapsed patients and
prolonged PFS [20, 23, 24]. These data strongly support the
evaluation of the combination of lenalidomide/dexametha-
sone plus bortezomib and elotuzumab within the context of
an intensified therapy in newly diagnosed patients.
Within the GMMG-HD6 trial the best of four treatment
strategies with respect to the PFS shall be determined. The
four treatment strategies differ in the use of elotuzumab in
addition to the background treatment of VRD induction/
consolidation therapy (VRD +/- elotuzumab) and lenalido-
mide maintenance treatment (lenalidomide +/- elotuzu-
mab), respectively.
The GMMG-HD6 trial will be the first phase III trial
investigating the role of elotuzumab in combination with
VRD and/or lenalidomide maintenance within a high dose
concept. Results will be interpreted on the background of
state of the art molecular profiling and imaging.
Methods
Design
GMMG-HD6 has a study population of 564 newly diag-
nosed multiple myeloma (NDMM) patients. It is a pro-
spective, multicenter, randomized, parallel group, open,
phase III clinical trial. There will be no blinding in this
trial due to differences in the patient management in the
treatment arms (premedication previous to application
of elotuzumab and additional intravenous infusions for
elotuzumab).
Trial objectives
Primary objective
The primary objective of the study is the determination
of the best of four treatment strategies regardingprogression-free survival (PFS) - defined as time from
randomization to progression or death from any cause
whichever occurs first, censored at the end of the study.
The four treatment strategies are:
1. (arm A1): VRD (Bortezomib (Velcade) /
Lenalidomide (Revlimid) / Dexamethasone)
induction, intensification, VRD consolidation and
lenalidomide maintenance,
2. (arm A2): VRD induction, intensification, VRD +
elotuzumab consolidation and lenalidomide
maintenance + elotuzumab,
3. (arm B1): VRD + elotuzumab induction,
intensification, VRD consolidation and lenalidomide
maintenance,
4. (arm B2): VRD + elotuzumab induction,
intensification, VRD + elotuzumab consolidation
and lenalidomide maintenance + elotuzumab.
Secondary objectives
The secondary objectives of this trial are to assess and to
compare treatment arms regarding
 overall survival (OS)
 CR rates after induction therapy
 CR rates after consolidation treatment
 best response to treatment during the study
 MRD-negativity measured by flow (FACS) and next
generation sequencing (NGS)
 time to progression (TTP), censored at end of trial
 duration of response (DOR), censored at end
of trial
 toxicity during induction treatment, consolidation
and maintenance treatment with respect to adverse
events of CTCAE grade ≥ 3
 quality of life assessment of patients at baseline,
during induction treatment, consolidation and
maintenance treatment. Assessment of quality
of life is performed using patient self-report
questionnaires of the European Organization
for Research and Treatment of Cancer Quality
of Life Questionnaire (EORTC- QLQC30)
including the multiple myeloma module
(EORTC-QLQMY20).
Setting
GMMG-HD6 is an investigator initiated trial by the
German-speaking Myeloma Multicenter Group (GMMG)
with a multicenter design.
Estimated timeline
The duration of the trial for each patients is expected to
be 36-39 months (induction and intensification treatment:
7-10 months, 3 months rest between intensification and
Table 1 Inclusion and exclusion criteria for the GMMG-HD6 trial
Inclusion criteria
Patients meeting all of the following criteria will be considered for admission to the trial:
Confirmed diagnosis of untreated multiple myeloma requiring systemic therapy (diagnostic criteria (IMWG updated criteria (2014). For some patients
systemic therapy may be required though these diagnostic criteria are not fulfilled. In this case the GMMG study office has to be consulted prior to
inclusion.
Measurable disease, defined as any quantifiable monoclonal protein value, defined by at least one of the following three measurements
Serum M-protein ≥10 g/l (for IgA ≥ 5 g/l)
Urine light-chain (M-protein) of ≥200 mg/24 h
Serum FLC assay: involved FLC level ≥ 10 mg/dl provided sFLC ratio is abnormal
Age 18–70 years inclusive
WHO performance status 0–3 (WHO = 3 is allowed only if caused by MM and not by co-morbid conditions)
Negative pregnancy test at inclusion (women of childbearing potential)
For all men and women of childbearing potential: patients must be willing and capable to use adequate contraception during the complete therapy.
Patients must agree on the requirements regarding the lenalidomide pregnancy prevention programme.
All patients must
agree to abstain from donating blood while taking lenalidomide and for 28 days
following discontinuation of lenalidomide therapy
agree not to share study drug lenalidomide with another person and to return all
unused study drug to the investigator or pharmacist
Ability of patient to understand character and individual consequences of the clinical trial
Written informed consent (must be available before enrollment in the trial)
Exclusion criteria
Patients presenting with any of the following criteria will not be included in the trial:
Patient has known hypersensitivity to any drugs given in the protocol, notably bortezomib, lenalidomide, dexamethasone and elotuzumab or to any of the
constituent compounds (incl. Boron and mannitol).
Systemic AL amyloidosis (except for AL amyloidosis of the skin or the bone marrow)
Previous chemotherapy or radiotherapy during the past 5 years except local radiotherapy in case of local myeloma progression. (Note: patients may have
received a cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy within 4 weeks prior to study entry.)
Severe cardiac dysfunction (NYHA classification III-IV, see appendix IIIB)
Significant hepatic dysfunction (serum bilirubin ≥1,8 mg/dl and/or ASAT and/or ALAT
≥ 2.5 times normal level), unless related to myeloma. (Note: if the mentioned limits for bilirubin or ASAT/ALAT are exceeded, but there is no significant
hepatic dysfunction at investigator’s discretion, the GMMG study office has to be consulted prior to inclusion)
Patients with renal insufficiency requiring hemodialysis
HIV positivity
Patients with active or history of hepatitis B or C
Patients with active, uncontrolled infections
Patients with peripheral neuropathy or neuropathic pain, CTC grade 2 or higher (as defined by the NCI Common Terminology Criteria for Adverse Events
(NCI CTCAE) Version 4.0, see appendix V)
Patients with a history of active malignancy during the past 5 years with the exception of basal cell carcinoma of the skin or stage 0 cervical carcinoma
treated with curative intent
Patients with acute diffuse infiltrative pulmonary and/or pericardial disease
Autoimmune hemolytic anemia with positive Coombs test or immune thrombocytopenia
Platelet count < 75 × 109/l, or, dependent on bone marrow infiltration by plasma cells, platelet count < 30 × 109/l (patients with platelet count < 75 × 109/l,
but > 30 × 109/l may be eligible if percentage of plasma cells in bone marrow is ≥50%), (transfusion support within 14 days before the test is not allowed)
Haemoglobin < 8.0 g/dl, unless related to myeloma
Absolute neutrophil count (ANC) < 1.0 × 109/l (the use of colony stimulating factors within 14 days before the test is not allowed), unless related to
myeloma
Pregnancy and lactation
Participation in other clinical trials. This does not include long-term follow-up periods without active drug treatment of previous studies during the last 6
months.
No patient will be allowed to enrol in this trial more than once.
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phase 24 months) The overall duration of the trial is ex-
pected to be approximately 8 years including preparatory
phase. Recruitment of patients has started in Q2 2015. The
actual overall duration or recruitment may vary.
 Total trial duration: [96 months]
 Duration of the clinical phase: [74 months]
 Beginning of the preparatory phase: [Q1 2014]
 FPI (First Patient In): [Q4 2015]
 LPI (Last Patient In): [Q4 2017]
 LPO (Last Patient Out): [Q1 2021]
 DBL (Data Base Lock): [Q3 2021]
 Statistical analyses completed: [Q4 2021]
 Trial report completed: [Q1 2022]
Ethical aspects, safety, consent
This study protocol is compliant with the declaration of
Helsinki, the International Conference on
Harmonization of Good Clinical Practice (ICH-GCP)
guidelines, German law, regulations and organizations.
A Data Safety Monitoring Board (DSMB) was installed
before the start of the trial. The ethics committees/insti-
tutional review boards of all study sites gave a written
approval before the start of this study.
Patients have to give written informed consent before
any procedures regarding the trial are performed.
In the patient case report forms AEs are recorded and
an assessment by the Investigator will be performed re-
garding intensity (according to CTCAE v4.0), serious-
ness and relatedness to the medication that is provided
in the study.
For serious AEs (SAEs) there is an extra form that has to
be filled out by the Investigator. This form has to be sent to
the study administration within 24 hours after detection of
the SAE. If a Suspected Unexpected Serious Adverse Reac-
tion (SUSAR) occurs it will be reported to all investigators,
ethics committees and the federal authorities.
Selection of trial patients
Inclusion and exclusion criteria are listed in Table 1.
Trial procedures
Randomisation and stratification
The patient has to be registered before the start of ther-
apy. Patients need to be registered at the GMMG study
office by sending the “Registration and Randomisation
Form” by fax.
The following lab results are already necessary at
registration, in addition to information regarding the eli-
gibility criteria and the investigational site:
 Serum β-2 microglobulin value
 Serum albumin value Serum M-protein (concentration of monoclonal pro-
tein in serum)
 Urine M-protein (Bence Jones).
All eligibility criteria will be checked with a check-
list. ISS stage will be calculated from the provided
serum β-2 microglobulin value and serum albumin
value in serum. If the patient needs to be registered
before the requested lab results are available, the
GMMG study office has to be consulted so that the
patient can be included. The necessary laboratory in-
vestigations have to be initiated before start of treat-
ment and the results have to be submitted to the
GMMG study office as soon as possible. Each patient
will be given a unique patient study number (“ran-
domisation number”). Patients will be randomized
using block randomization stratified by ISS stage (I
vs. II vs. III) in order to achieve a balance of treat-
ment groups with respect to this prognostic covariate.
There will be no additional stratification by center.
Influence of this covariate is considered to be less
because of the long trial experience of most centers
within the GMMG.
The probability for assignment in each of the four
treatment arms (A1, A2, B1, B2) is 25%, the relation of
treatment arms is 1:1:1:1.
Patient study number and result of randomization will
be sent to the investigator by fax.Screening
All patients have to undergo physical examination in-
cluding assessment of WHO performance score, body
weight, body height and concomitant diseases.
Before the inclusion into the trial for a patient is pos-
sible, the following laboratory investigations are neces-
sary: C reactive protein, lactate dehydrogenase, β-2
microglobulin, albumin, total protein, pregnancy test
(only for woman in childbearing age), immunoglobulins,
monoclonal protein and free light chains in serum,
monoclonal protein in urine, immunofixation in serum,
immunofixation in urine, complete blood count includ-
ing Absolute Neutrophil Count (ANC), electrolytes,
renal parameters, hepatic parameters, thyroid stimulat-
ing hormone.
A bone marrow puncture has to be performed for
bone marrow aspiration (cytology, iFISH) and bone mar-
row histology.
For the documentation of the skeletal status medical
imaging with low dose, whole body computed tomog-
raphy or conventional X-ray imaging is required.
An ECG and an echocardiogram have to be performed
prior to study inclusion to document the cardiac condi-
tion of the patient.
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Monitoring will be done by personal visits from a clin-
ical monitor according to SOPs of the coordination cen-
ters for clinical trials (KKS).
The monitor will review the entries into the CRFs on
the basis of source documents (source data verification).
The investigator must allow the monitor to verify all es-
sential documents and must provide support at all times
to the monitor.
By frequent communications (letters, telephone, fax),
the site monitor will ensure that the trial is conducted
according to the protocol and regulatory requirements.
Timepoints of clinical evaluations
The Table 2 shows the recommended timepoints of re-
sponse evaluation. A non-essential deviation of these
timepoints (e.g. for logistic reasons) is accepted, but it is
important that the response to a treatment period will be
assessed previous to the start of the subsequent period.
Trial treatment
Figure 1 includes a compact overview of the trial treatment.
After the inclusion in the study, all patients regardless
of randomization will receive an induction treatment
consisting of 4 VRD cycles of 21 days each (bortezomib
1.3 mg/m2 s.c. on days 1,4,8,11, oral lenalidomide 25 mg
on days 1-14, oral dexamethasone 20 mg on days
1,2,4,5,8,9,11,12, additionally in cycle 1 and 2 on day 15).
Patients in arm B1 and B2 will additionally be treated
with elotuzumab 10 mg/kg on days 1,8,15 in cycle 1 and
2, days 1 and 11 in cycles 3 and 4.
All eligible patients will be given an intensified ther-
apy regime according to GMMG standard protocols.
A commonly used regimen for intensified therapy is:
stem cell collection after CAD mobilization followedTable 2 Recommended timepoints of response evaluation
Treatment period Timepoint of response ev
After induction treatment d21 – d35 after start of 4t
After first chemotherapy cycle of intensification
regime (mobilization)
d23 – d33 after start of th
After subsequent chemotherapy cycles of inten
sification regime
According to local policy:
to next cycle)
After VRD consolidation d21–35 after start of 2nd c
During maintenance every 3 months
Follow up, i.e. after individual “end of study”,
(until 1st PD)
Evaluation is recommende
pecially no progressive dis
timepoint of diagnosis of
correspond to a regular 3
Follow up, after 1st PD There are no specific reco
disease and therapies for
adapted to the requireme
in FU after 1st PD are as f
Information on secondary
“PD”). Each line of therapyby high dose melphalan (200 mg/m2) and autologous
stem cell rescue. GMMG standard is a single HDT and
ASCT for patients who reach at least a CR and tandem
HDT and ASCT for patients who do not reach CR. Al-
though the details of stem cell collection, HDT and
ASCT are not specified in the study protocol.
Three months after the beginning of the last HDT
cycle patients should receive consolidation treatment
consisting of 2 cycles of VRD of 21 days each with
weekly administration of bortezomib (bortezomib 1.3
mg/m2 s.c. on days 1,8,15, oral lenalidomide 25 mg
on days 1-14, oral dexamethasone 20 mg on days
1,2,8,9,15,16). Patients in arm A2 and B2 will be
treated with elotuzumab 10 mg/kg additionally in
both cycles on days 1,8,15.
Maintenance therapy should start on d35 of the
second VRD consolidation cycle and will be given
until confirmed progression, for 2 years or until un-
acceptable toxicity, whichever occurs first. All pa-
tients should receive 26 cycles lenalidomide
maintenance every 28 days (oral lenalidomide 10 mg
d 1-28) together with dexamethasone (12 mg on
days 1 and 15 in cycle 1-6 and day 1 thereafter). Pa-
tients in arm A2 and B2 will be treated with
Elotuzumab 10 mg/kg i.v. additionally on days 1 and
15 in cycle 1-6 and day 1 thereafter). A two years
maintenance therapy timeframe was chosen to define
a clear endpoint for the trial as required by the
German authorities. Benefits of prolonged mainten-
ance therapy beyond 2 years had not been shown in
trials at the time of submission of this study protocol.
Nonetheless, after the end of the study, all patients not
encountering disease progression or inacceptable toxicity
are suggested continuing lenalidomide maintenance
treatment.aluation
h cycle VRD
is cycle (previous to high dose therapy)
d60 - d90 after start of high dose therapy cycle recommended (previous
ycle VRD
d every 3 months. As long as there is no change in response status, es-
ease, CRF documentation of the FU visit is sufficient every 6 months. The
progressive disease has to be documented in the eCRF, even if it doesn’t
- or 6-month visit, respectively.
mmendations for the evaluation schedule after 1st PD as course of the
relapsed and/or refractory myeloma vary and the visits have to be
nts of the individual patient. The requirements for eCRF documentation
ollows: update of the survival status at least every 6 months (incl.
primary malignancies and on the timepoint of diagnosis of subsequent
should be recorded separately
Fig. 1 GMMG HD6 trial overview
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It is mandatory to give anti-viral (Aciclovir 2 x 400 mg/d
p.o.) and anti-bacterial (Cotrimoxazol 2 x 960 mg/d p.o.
or Ciprofloxacin 2 x 500 mg/d p.o.) prophylactic treat-
ment to all patients during induction and consolidation
therapy. A venous thromboembolism (VTE) prophylaxis
in conjunction with VRD (+/- elotuzumab) has to be
given. It is recommended to give acetylsalicylic acid
(ASA) 100 mg daily. Patients at an individual high risk
of thromboembolic events, such as patients with
previous history of thromboembolism, should receive a
VTE prophylaxis with low molecular weight heparin
(LMWH). It is strongly recommended to start treatment
with i.v. bisphosphonates at diagnosis and to continue
this treatment every 4 weeks for at least 2 years. A com-
monly used regimen consists of zoledronate 4 mg or
pamidronate 90mg once every 4 weeks. Elotuzumab re-
quires premedication with H1 blocker, H2 blocker and
paracetamol administered 30-90 minutes prior to elotu-
zumab administration and i.v. dexamethasone at least 45
minutes prior to elotuzumab.
Concomitant medication and treatment
Bisphosphonate treatment is recommended for all pa-
tients in the trial. It is permitted to treat trial partici-
pants with red blood- and platelet-transfusions, G-CSF
and intravenous immunoglobulins. Furthermore, it isallowed to treat myeloma- or treatment-related com-
plications (e.g. vertebroplasty in case of vertebral
compression fracture). Radiotherapy is permitted.
Additional use of substances with antineoplastic fea-
tures is not allowed.Follow up
Regular follow ups after the discontinuation of the study
treatment are part of the study protocol. During this
timeframe additional data regarding survival, toxicities,
efficacy and subsequent myeloma-specific treatment will
be gathered.Response assessment
Response will be assessed according to the International
Myeloma Working Group (IMWG) uniform response
criteria [25]. In addition and modification to the IMWG
criteria “minimal response” (MR) as defined in the
EBMT criteria [26], “near CR” (nCR) and “molecular
CR” (mCR) have been added. According to the trial
protocol, in case of a suspected CR based on routine
testing at any time during therapy, a bone marrow punc-
ture is performed to confirm the response. At the same
time, MRD-analysis is performed. If CR is confirmed
MRD assessment is repeated once after 6 months.
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Discontinuation of trial participation of individual patients
The patient can discontinue the trial treatment at any
point without having to give any reason. The investigator
can stop the trial treatment for patients if further treat-
ment could be harmful or disadvantageous for the pa-
tient, if exclusion criteria are met, if a SAE occurs that
precludes further treatment, if a trial participant gets
pregnant, if data acquisition is not possible due to pa-
tient incompliance and if serological PD or PD with end
organ damage (CRAB criteria [27]) is present in the trial
patient. The only exception for PD is the occurrence of
PD after induction therapy or stem cell apheresis. In this
case further treatment in the trial is possible.
Closure of individual trial sites
Individual trial sites can be closed if the data quality is
not sufficient or if the trial site provides inadequate pa-
tient recruiting.
Premature termination of the trial
If unknown risks occur during the trial; or due to inad-
equate recruiting not enough patients are acquired to
continue the study, the DSMB or the principal investiga-
tor may terminate the trial prematurely.
Statistical analysis
Sample size calculation
The GMMG-HD6 trial is designed to determine as pri-
mary objective the best of the four treatment arms with
regard to progression-free survival (PFS), censored at
end of trial. Assuming 2 years of recruitment, 3 years
minimal follow-up time after end of recruitment, a total
of 10% drop-outs and 5% high risk patients leaving the
study prematurely after induction therapy, inclusion of
564 patients allows for rejecting the global null hypoth-
esis of no difference between the four arms at the
two-sided significance level of 5% with a power of 91%,
if the arms achieve PFS rates of 60%, 70%, 70% and 80%
after 3 years. This corresponds to hazard ratios relative
to the worst arm of 0.698, 0.698 and 0.437. The PFS
rates of the intermediate arms are conservatively chosen
representing the least favorable distribution with respect
to power. Further treatment comparisons will be realized
within a closed testing procedure. The sample size calcu-
lation is based on the method of Barthel et al. for
multi-arm survival trials [28]. An interim analysis with
respect to PFS rates will be conducted after 2.5 years to
rule out lack of efficacy. The strongest observed effect
between the best and the worst arm will be used to rec-
ommend a potential stop for futility based on the condi-
tional power (CP) as proposed by Lachin (2005) [29].
The study is recommended to be stopped if CP ≤ 20%. This
possibility to stop for futility results in a power loss ofmaximally 9.6%, thus, the overall power to reject the global
null hypothesis of no difference between the four arms
achieves at least 81.4%. Assuming arm A1 as reference, we
are mainly interested in the best-versus-reference compari-
son. Liu and Dahlberg [30] found for the comparison of
the best versus reference arm that the power lies only
slightly below the overall power of the study. Our own
simulation studies under the specific study assumptions
confirmed these results and showed 88.6% power for the
best-versus-reference comparison. With the possibility to
stop at interim if CP ≤ 20%, the power for the
best-versus-reference comparison would still be larger
than 79%.
Statistical methods
A detailed statistical analysis plan (SAP) will be finalized
before closure of the database and the final analysis
which has to be authorized by the biometrician, the
sponsor, and the LKP. The analysis of the primary end-
point is confirmatory. All remaining analyses are ex-
ploratory and will be carried out at a two-sided
significance level of 0.05 unless noted otherwise.
Primary endpoint
The primary endpoint is PFS, censored at end of trial. The
four treatment arms will be compared in a closed testing
procedure as introduced by Marcus, Peritz and Gabriel
[26]. This hierarchical step-down approach controls the
family-wise error rate in a multi-comparison setting if all
null hypotheses are tested in a pre-defined hierarchical
order at a the same significance level starting with the glo-
bal null hypothesis of no treatment difference between the
four arms down to the pairwise (elementary) null hypoth-
eses of no treatment difference between two treatment
arms. All null hypotheses will be tested confirmatory at
the two-sided 5% significance level using the log-rank test
stratified by ISS stage. Statistically significant different PFS
of a treatment arm with respect to a comparator arm will
be concluded if the adjusted p-value of the elementary hy-
pothesis is below 0.05.
The analysis of the primary objective is performed
after database closure and will be presented in the final
biometrical report.
Discussion
An intensified treatment concept including induction
therapy, high dose melphalan (200 mg/m2) and subse-
quent consolidation/maintenance therapy is considered
the standard treatment for fit MM patients [1, 2].
Results of randomized phase III trials comparing HDT
with treatment including new drugs showed a benefit for
HDT in response, minimal residual disease (MRD) and
PFS [10, 31–33]. The data from the French study
showed a strong correlation between MRD negativity
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sions in PET-CT before maintenance [34, 35]. Molecular
data before treatment and MRD-monitoring during treat-
ment will allow to define a subgroup of MM patients that
can be cured. In addition to testing the anti-SLAMF7 anti-
body elotuzumab in upfront induction and maintenance
treatment of transplant-eligible patients, the CD38 targeting
antibodies daratumumab and isatuximab are currently
tested in ongoing trials, e.g. by the Intergroupe Franco-
phone du Myélome (IFM) (Cassiopeia, NCT02541383).
Given the previously described study results in the re-
lapsed setting, an improvement of the therapeutic results
by the addition of the humanized monoclonal antibody elo-
tuzumab can be expected. This phase III trial is designed to
evaluate whether the addition of elotuzumab to an intensi-
fied treatment concept with high dose melphalan chemo-
therapy plus autologous stem cell transplantation and
induction, consolidation and maintenance treatment with
bortezomib and lenalidomide is able to improve PFS com-
pared to the same concept without elotuzumab.
Conclusion
We present the study protocol of the first phase III
investigator initiated trial to explore the role of elotu-
zumab in combination with VRD and lenalidomide
maintenance together with high dose melphalan and
stem cell transplantation.
Results will be analyzed in comparison with molecular
profiling and imaging.
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